HIV testing and prophylaxis to prevent mother-to-child transmission in the United States
- PMID: 18977995
- DOI: 10.1542/peds.2008-2175
HIV testing and prophylaxis to prevent mother-to-child transmission in the United States
Abstract
Universal HIV testing of pregnant women in the United States is the key to prevention of mother-to-child transmission of HIV. Repeat testing in the third trimester and rapid HIV testing at labor and delivery are additional strategies to further reduce the rate of perinatal HIV transmission. Prevention of mother-to-child transmission of HIV is most effective when antiretroviral drugs are received by the mother during her pregnancy and continued through delivery and then administered to the infant after birth. Antiretroviral drugs are effective in reducing the risk of mother-to-child transmission of HIV even when prophylaxis is started for the infant soon after birth. New rapid testing methods allow identification of HIV-infected women or HIV-exposed infants in 20 to 60 minutes. The American Academy of Pediatrics recommends documented, routine HIV testing for all pregnant women in the United States after notifying the patient that testing will be performed, unless the patient declines HIV testing ("opt-out" consent or "right of refusal"). For women in labor with undocumented HIV-infection status during the current pregnancy, immediate maternal HIV testing with opt-out consent, using a rapid HIV antibody test, is recommended. Positive HIV antibody screening test results should be confirmed with immunofluorescent antibody or Western blot assay. For women with a positive rapid HIV antibody test result, antiretroviral prophylaxis should be administered promptly to the mother and newborn infant on the basis of the positive result of the rapid antibody test without waiting for results of confirmatory HIV testing. If the confirmatory test result is negative, then prophylaxis should be discontinued. For a newborn infant whose mother's HIV serostatus is unknown, the health care professional should perform rapid HIV antibody testing on the mother or on the newborn infant, with results reported to the health care professional no later than 12 hours after the infant's birth. If the rapid HIV antibody test result is positive, antiretroviral prophylaxis should be instituted as soon as possible after birth but certainly by 12 hours after delivery, pending completion of confirmatory HIV testing. The mother should be counseled not to breastfeed the infant. Assistance with immediate initiation of hand and pump expression to stimulate milk production should be offered to the mother, given the possibility that the confirmatory test result may be negative. If the confirmatory test result is negative, then prophylaxis should be stopped and breastfeeding may be initiated. If the confirmatory test result is positive, infants should receive antiretroviral prophylaxis for 6 weeks after birth, and the mother should not breastfeed the infant.
Comment in
-
Routine newborn HIV testing: an idea whose time has come.Pediatrics. 2009 Feb;123(2):e362-3; author reply e363. doi: 10.1542/peds.2008-3331. Pediatrics. 2009. PMID: 19171595 No abstract available.
Similar articles
-
HIV infection and zidovudine use in childbearing women.Pediatrics. 2004 Dec;114(6):e707-12. doi: 10.1542/peds.2004-0414. Epub 2004 Nov 15. Pediatrics. 2004. PMID: 15545619
-
Diagnosis of HIV-1 infection in children younger than 18 months in the United States.Pediatrics. 2007 Dec;120(6):e1547-62. doi: 10.1542/peds.2007-2951. Pediatrics. 2007. PMID: 18055670 Review.
-
ACOG committee opinion number 304, November 2004. Prenatal and perinatal human immunodeficiency virus testing: expanded recommendations.Obstet Gynecol. 2004 Nov;104(5 Pt 1):1119-24. Obstet Gynecol. 2004. PMID: 15516421
-
From research to practice: use of short course zidovudine to prevent mother-to-child HIV transmission in the context of routine health care in Northern Thailand.Southeast Asian J Trop Med Public Health. 1998 Sep;29(3):429-42. Southeast Asian J Trop Med Public Health. 1998. PMID: 10437936
-
International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update.Am J Obstet Gynecol. 2007 Sep;197(3 Suppl):S42-55. doi: 10.1016/j.ajog.2007.03.001. Am J Obstet Gynecol. 2007. PMID: 17825650 Review.
Cited by
-
Family-centred approaches to the prevention of mother to child transmission of HIV.J Int AIDS Soc. 2010 Jun 23;13 Suppl 2(Suppl 2):S2. doi: 10.1186/1758-2652-13-S2-S2. J Int AIDS Soc. 2010. PMID: 20573284 Free PMC article. Review.
-
False-positive human immunodeficiency virus enzyme immunoassay results in pregnant women.PLoS One. 2011 Jan 27;6(1):e16538. doi: 10.1371/journal.pone.0016538. PLoS One. 2011. PMID: 21304592 Free PMC article.
-
Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco.PLoS One. 2010 Jun 10;5(6):e11068. doi: 10.1371/journal.pone.0011068. PLoS One. 2010. PMID: 20548786 Free PMC article.
-
Women's willingness to be tested for human immunodeficiency virus during pregnancy: A review.World J Virol. 2015 Aug 12;4(3):245-54. doi: 10.5501/wjv.v4.i3.245. World J Virol. 2015. PMID: 26279985 Free PMC article. Review.
-
Management of HIV Infection during Pregnancy in the United States: Updated Evidence-Based Recommendations and Future Potential Practices.Infect Dis Obstet Gynecol. 2016;2016:7594306. doi: 10.1155/2016/7594306. Epub 2016 Jul 18. Infect Dis Obstet Gynecol. 2016. PMID: 27504071 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical